Role of randomized phase III trials in an era of effective targeted therapies

Nature Reviews Clinical Oncology

Volumn 9, Issue 4, 2012, Pages 208-214

  Sharma, Manish R ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; GEFITINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; INIPARIB; PACLITAXEL; PLACEBO; RETINOIC ACID; RITUXIMAB; VEMURAFENIB; VISMODEGIB;

ACUTE GRANULOCYTIC LEUKEMIA; BASAL CELL CARCINOMA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK BENEFIT ANALYSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84859377987     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.190     Document Type: Review

References (69)

1. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00405587.
2. Flaherty, K. et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer [abstract]. J. Clin. Oncol. 27 (Suppl. 15), 9000 (2009).
3. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
4. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00405587.
5. Roche. Roche personalized investigational medicine shows survival benefit in advanced skin cancer [online], http://www.roche.com/media/media-releases/ med-cor-2011-01-19.htm (2011).
6. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
7. FDA. Highlights of prescribing information for Zelboraf (vemurafenib) [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202429s000lbl.pdf (2011).
8. Harmon, A. New drugs stir debate on rules of clinical trials. The New York Times (New York) A1 (19 Sept 2010).
9. Miller, F. G. & Joffe, S. Equipoise and the dilemma of randomized clinical trials. N. Engl. J. Med. 364, 476-480 (2011).
10. Miller, F. G. & Joffe, S. Balancing access and evaluation in the approval of new cancer drugs. JAMA 305, 2345-2346 (2011).
11. Joffe, S. & Miller, F. G. Equipoise: Asking the right questions for clinical trial design. Nat. Rev. Clin. Oncol. (in press)
12. PhRMA. More than 800 medicines and vaccines in testing offer hope in the fight against cancer [online], http://www.healthinfoispower.files.wordpress.com/ 2009/04/phrmacancer.pdf (2009).
13. Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572 (1988).
14. Soignet, S. L. et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339,1341-1348 (1998).
15. Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195 (1997).
16. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
17. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
18. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009).
19. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
20. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237-2246 (2003).
21. Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
22. Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
23. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
24. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005).
25. Tamura, K. & Fukuoka, M. Gefitinib in non-small cell lung cancer. Expert Opin. Pharmacother. 6, 985-993 (2005).
26. Sanford, M. & Scott, L. J. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs 69, 2303-2328 (2009).
27. Sequist, L. V., Bell, D. W., Lynch, T. J. & Haber, D. A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25, 587-595 (2007).
28. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
29. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
30. Keedy, V. L. et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29, 2121-2127 (2011).
31. Department of Health and Human Services. New drug, antibiotic, and biological drug product regulations; accelerated approval-FDA. Final rule. Fed. Regist. 57, 58942-58960 (1992).
32. Johnson, J. R. et al. Accelerated approval of oncology products: the food and drug administration experience. J. Natl. Cancer Inst. 103, 636-644 (2011).
33. Food and Drug Administration Oncologic Drugs Advisory Committee. Transcript of the 8 February meeting, [online] http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM245644.pdf (2011).
34. Tsimberidou, A. M., Braiteh, F., Stewart, D. J. & Kurzrock, R. Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J. Clin. Oncol. 27, 6243-6250 (2009).
35. Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244-3254 (2001).
36. FDA. Pfizer voluntarily withdraws cancer treatment Mylotarg from U. S. market [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm216448.htm (2010).
37. Sharma, M. R., Stadler, W. M. & Ratain, M. J. Randomized phase II trials: a long-term investment with promising returns. J. Natl. Cancer Inst. 103, 1093-1100 (2011).
38. FDA. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics [online], http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (2007).
39. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
40. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
41. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
42. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2007).
43. Rini, B. I. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
44. Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
45. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
46. Van Cutsem, E. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
47. Tang, P. A., Bentzen, S. M., Chen, E. X. & Siu, L. L. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J. Clin. Oncol. 25, 4562-4568 (2007).
48. Buyse, M. et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J. Clin. Oncol. 25, 5218-5224 (2007).
49. Lara, P. N. Jr. et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J. Clin. Oncol. 26, 463-467 (2008).
50. Halabi, S. et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J. Clin. Oncol. 27, 2766-2771 (2009).
51. Heng, D. Y. et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 117, 2637-2642 (2011).
52. Cheng, S. K., Dietrich, M. S. & Dilts, D. M. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin. Cancer Res. 16, 5557-5563 (2010).
53. Hamilton, E. P., Lyman, G. H. & Peppercorn, J. Availability of experimental therapy outside oncology randomized clinical trials in the United States. J. Clin. Oncol. 28, 5067-5073 (2010).
54. Schilsky, R. L. Accrual to cancer clinical trials in the era of molecular medicine. Sci. Transl. Med. 3, 75cm9 (2011).
55. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
56. D'Agostino, R. B. Sr. Changing end points in breast-cancer drug approval-the Avastin story. N. Engl. J. Med. 365, e2 (2011).
57. Online reference. http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2008/125085s091ltr.pdf (2008).
58. Food and Drug Administration Oncologic Drugs Advisory Committee. Transcript of the 20 July meeting [online], http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM221998.pdf (2010).
59. O'Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011).
60. Anders, C. K. et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin. Cancer Res. 16, 4702-4710 (2010).
61. Pollack, A. Promising results in stomach and breast cancer drugs. The New York Times (New York) (1 June 2009).
62. O'Shaughnessy, J. et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a1007 (2011).
63. Richey, E. A. et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J. Clin. Oncol. 27, 4398-4405 (2009).
64. Psaty, B. M. & Prentice, R. L. Minimizing bias in randomized trials: the importance of blinding. JAMA 304, 793-794 (2010).
65. Burzykowski, T. et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J. Clin. Oncol. 26, 1987-1992 (2008).
66. Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935-942 (2002).
67. Inoue, L. Y., Thall, P. F. & Berry, D. A. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58, 823-831 (2002).
68. Korn, E. L. & Freidlin, B. Outcome-adaptive randomization: is it useful? J. Clin. Oncol. 29, 771-776 (2011).
69. Berry, D. A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2012).